Cushingoid
Showing 1 - 25 of 306
Adrenocortical Carcinoma Trial in United States (Relacorilant, Pembrolizumab)
Recruiting
- Adrenocortical Carcinoma
-
Stanford, California
- +5 more
Jun 27, 2022
Duchenne Muscular Dystrophy Trial in Columbus (Prednisolone)
Recruiting
- Duchenne Muscular Dystrophy
-
Columbus, OhioNationwide Children's Hospital
Jun 7, 2022
Post COVID-19 Diffuse Lung Disease Trial in Chandigarh (Medium dose prednisolone, Low dose prednisolone)
Completed
- Post COVID-19 Diffuse Lung Disease
- Medium dose prednisolone
- Low dose prednisolone
-
Chandigarh, IndiaPostgraduate Institute of Medical Education and Research
Apr 25, 2022
Allergic Bronchopulmonary Aspergillosis Trial in Chandigarh (Deflazacort, Prednisolone)
Recruiting
- Allergic Bronchopulmonary Aspergillosis
-
Chandigarh, IndiaChest Clinic, Dept. of Pulmonary Medicine
Feb 22, 2021
Colitis, Ulcerative Trial in Worldwide (Cobitolimod, Placebo)
Muscular Dystrophy, Duchenne Trial in United States (Spironolactone, Prednisolone)
Terminated
- Muscular Dystrophy, Duchenne
-
Iowa City, Iowa
- +3 more
Jan 19, 2022
Childhood Brain Tumors Trial in Houston (Antineoplaston therapy (Atengenal + Astugenal))
Completed
- Childhood Brain Tumors
- Antineoplaston therapy (Atengenal + Astugenal)
-
Houston, TexasBurzynski Clinic
Mar 3, 2022
Congenital Adrenal Hyperplasia Trial run by the (Chronocort)
Not yet recruiting
- Congenital Adrenal Hyperplasia
-
Bethesda, MarylandNational Institutes of Health Center
Mar 18, 2022
Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV) Trial in Baltimore (Chemotherapy with Temodar.,
Terminated
- Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)
- Chemotherapy with Temodar.
- Radiation therapy
-
Baltimore, MarylandUmmc Msgcc
Dec 1, 2022
Duchenne Muscular Dystrophy Trial in Vancouver (Vamorolone)
Recruiting
- Duchenne Muscular Dystrophy
-
Vancouver, British Columbia, CanadaBritish Columbia Children's Hospital
Mar 24, 2022
Iatrogenic Cushing's Disease Trial in Oxford (AZD4017 and prednisolone, Placebo Oral Tablet and prednisolone)
Completed
- Iatrogenic Cushing's Disease
- AZD4017 and prednisolone
- Placebo Oral Tablet and prednisolone
-
Oxford, United KingdomUniversity of Oxford
May 12, 2021
Limb-Girdle Muscular Dystrophy Trial in Worldwide (Deflazacort)
Terminated
- Limb-Girdle Muscular Dystrophy
-
Atlanta, Georgia
- +17 more
May 31, 2022
Malignant Mesothelioma Trial in Houston (Antineoplaston therapy (Atengenal + Astugenal))
Terminated
- Malignant Mesothelioma
- Antineoplaston therapy (Atengenal + Astugenal)
-
Houston, TexasBurzynski Clinic
Mar 31, 2021
Pediatric Ulcerative Colitis Trial (Vamorolone 4% suspension for oral dosing)
Withdrawn
- Pediatric Ulcerative Colitis
- Vamorolone 4% suspension for oral dosing
- (no location specified)
Sep 25, 2020
Multiple Myeloma Trial in New York (carfilzomib, Dexamethasone, Clarithromycin)
Active, not recruiting
- Multiple Myeloma
- carfilzomib
- +3 more
-
New York, New YorkWeill Cornell Medical College
Apr 10, 2022
Grade B aGVHD, Grade C aGVHD, Grade D aGVHD Trial in United States (remestemcel-L)
Completed
- Grade B aGVHD
- +2 more
-
Los Angeles, California
- +19 more
Feb 18, 2022
Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma Trial in Australia, Canada,
Completed
- Localized Resectable Neuroblastoma
- +4 more
- Clinical Observation
- +5 more
-
Birmingham, Alabama
- +103 more
Jan 4, 2023
Ornithine Transcarbamylase (OTC) Deficiency Trial in Worldwide (scAAV8OTC, Oral prednisone)
Completed
- Ornithine Transcarbamylase (OTC) Deficiency
- scAAV8OTC
- +2 more
-
Aurora, Colorado
- +8 more
Jan 23, 2023
Colon Cancer Trial in United States (Panitumumab, Nivolumab, Ipilimumab)
Glioblastoma, Recurrent Adult Brain Tumor, Malignant Glioma Trial in Richmond (sorafenib tosylate, valproic acid, sildenafil
Active, not recruiting
- Glioblastoma
- +3 more
- sorafenib tosylate
- +2 more
-
Richmond, VirginiaVirginia Commonwealth University/Massey Cancer Center
Mar 21, 2022
Brain Cancer Trial in Canada, United States (cetuximab in conjunction with external beam radiation therapy, followed by
Completed
- Brain Cancer
- cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
-
Phoenix, Arizona
- +11 more
Mar 2, 2022